Cargando…

Prevalence of Cirrhosis/Advanced Fibrosis Among HBsAg-Negative and HBcAb-Positive US Adults: A Nationwide Population-Based Study

INTRODUCTION: Evaluation of cirrhosis appears to be easily overlooked in the clinic for the HBsAg-negative (hepatitis B surface antigen-negative) and HBcAb-positive (hepatitis B core antibody-positive) population. Herein, we determine the prevalence of cirrhosis/advanced fibrosis among HBsAg-negativ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Shuai-Wen, Chen, Chen, Kong, Hong-Yan, Huang, Jia-Quan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617979/ https://www.ncbi.nlm.nih.gov/pubmed/35934762 http://dx.doi.org/10.1007/s40121-022-00680-2

Ejemplares similares

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis
por: Morisco, Filomena, et al.
Publicado: (2014)

Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia
por: Toscanini, Federica, et al.
Publicado: (2011)

Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy
por: Lin, Ying-Cheng, et al.
Publicado: (2021)

HBsAb and HBcAb Have No Significant Effect on the Progression of SLE and RA
por: WANG, Fen, et al.
Publicado: (2017)

Risk of hepatitis B reactivation in HBsAg−/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta‐analysis
por: Hong, Xuezhi, et al.
Publicado: (2023)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
por: Cerva, Carlotta, et al.
Publicado: (2022)

Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study
por: Tien, Ya-Chih, et al.
Publicado: (2018)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023)

Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21
por: Giordano, Claudia, et al.
Publicado: (2023)

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
por: Shiraishi, Kana, et al.
Publicado: (2023)

HBcAb positivity increases the risk of postoperative complications after extended hemihepatectomy for hilar cholangiocarcinoma
por: Wang, Wen‐Qiang, et al.
Publicado: (2023)

De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor
por: Bedi, Harjot K., et al.
Publicado: (2021)

Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients
por: Wang, Wen-Xin, et al.
Publicado: (2022)

Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma
por: Masarone, Mario, et al.
Publicado: (2014)

Prevalence of Anti-HBc Antibodies among HBsAg Negative Individuals and Its Association with Occult Hepatitis B
por: Madhavan, Anitha, et al.
Publicado: (2021)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011)

Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment
por: Yin, Shengxia, et al.
Publicado: (2023)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis
por: ZHANG, LIN L., et al.
Publicado: (2020)

Prevalence of HBc-Ab among HBs-Ag negative healthy blood donors in south of Iran
por: Khorami, Farhad, et al.
Publicado: (2013)

Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs
por: Huang, Jing, et al.
Publicado: (2017)

What are the causes and outcomes of the coexistence of HBsAg and anti-HBs?
por: Afyon, Murat
Publicado: (2016)

Hepatitis B sero-prevalence among hematology patients: importance of Anti-HbcAb and efficiency of antiviral prophylaxis
por: Kantar, Funda Ugur, et al.
Publicado: (2022)

In vitro expression of precore proteins of hepatitis B virus subgenotype A1 is affected by HBcAg, and can affect HBsAg secretion
por: Deroubaix, Aurélie, et al.
Publicado: (2021)

RE: Risk of HBV Reactivation in HBsAg Negative and Anti-HBc IgG Positive Patients Receiving Biologic Therapy
por: Ergenç, İlkay, et al.
Publicado: (2023)

Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
por: Yan, Ying, et al.
Publicado: (2022)

Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B
por: Kwak, Min-Sun, et al.
Publicado: (2019)

Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012)

Assessment of noninvasive liver stiffness in inactive HBsAg carriers by transient elastography: Fibroscan in inactive HBsAg carriers
por: Sporea, Ioan, et al.
Publicado: (2011)

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
por: Salpini, Romina, et al.
Publicado: (2017)

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
por: Xie, Yandi, et al.
Publicado: (2023)

The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing
por: Wang, Ying, et al.
Publicado: (2021)

AUSTRALIA ANTIGEN (HBsAG) IN INSTITUTIONALISED SCHIZOPHRENICS
por: Chaudhury, S., et al.
Publicado: (1993)

HBsAg seroprevalence among Senegalese militaries
por: Ndiaye, Abdoul A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_d6nk27lk611qign1esai75iu5j